Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
· insidermonkey.com
Gilead Sciences, Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infec...